# HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial

> **NCT05886465** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 40 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Bevacizumab
- **PROCEDURE:** HAIC with FOLFOX

## Key facts

- **NCT ID:** NCT05886465
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-24
- **Primary completion:** 2024-06-01
- **Final completion:** 2024-12-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2023-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05886465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05886465, "HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05886465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*